ONCY Key Stats
- Oncolytics Biotech® Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference noodls Dec 3
- Oncolytics (ONCY) CEO Thompson to Present at Piper Jaffray Conference Street Insider Dec 3
- Needham & Company Perplexed by Oncolytics (ONCY) H&N Trial Data Release But 'Staying the Course' Street Insider Nov 25
- Oncolytics: One Drug To Treat Them All, Or A Complete Dud, Data Is Not Bad Seeking Alpha Nov 24
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of ONCOLYTICS BIOTECH INC. for Possible Violations of Federal Securities Laws Business Wire Nov 22
- Company Calls Cancer-Fighting Virus Study 'Positive' But Results Are Unconvincing Nov 21
- 2 Small Speculative Biotech Plays Moving On News Seeking Alpha Nov 21
- Oncolytics says Reolysin slows cancer progression Nov 21
- Oncolytics (ONCY) Higher Pre-market Following Positive Top-Line Data from REO 018 Study Street Insider Nov 21
- Oncolytics Biotech® Inc. Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers noodls Nov 21
ONCY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Oncolytics Biotech is down 17.16% over the last year vs S&P 500 Total Return up 30.43%, Jazz Pharmaceuticals up 129.5%, and Biodel down 13.49%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for ONCY
Pro Strategies Featuring ONCY
Did Oncolytics Biotech make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Oncolytics Biotech, Inc., is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers.